Merck & Co., Inc.'s third-quarter 2007 earnings call highlighted several positive trends and robust performance metrics that are likely to have a positive impact on the stock price in the short term:

1. **Strong Revenue Growth**: Merck reported a 12.3% increase in worldwide revenue, driven by the success of new vaccines like GARDASIL, ROTATEQ, and ZOSTAVAX, as well as strong performance from JANUVIA and JANUMET. This growth is expected to continue, with raised full-year EPS guidance to $3.08-$3.14, excluding restructuring charges[5].

2. **Market Leadership and Expansion**: The company's vaccines business saw a 124% increase in revenue, and GARDASIL has already achieved blockbuster status. Additionally, JANUVIA has become the second-leading branded oral antidiabetic agent in the U.S., and Merck is expanding its reach internationally[5].

3. **Operational Efficiencies and Cost Management**: Merck has improved product gross margins and reduced marketing and administrative expenses. The company is on track with its global restructuring program, aiming to eliminate 7,000 positions by the end of 2008, which will further enhance cost efficiency[5].

4. **Pipeline and R&D**: Merck continues to invest heavily in R&D, with several compounds in late-stage clinical trials and new partnerships, such as the licensing agreement with ARIAD Pharmaceuticals. This suggests a strong pipeline and potential for future growth[5].

Given these factors, the stock is likely to experience a positive impact in the short term due to the company's solid financial performance, strong product uptake, and optimistic outlook.

**Rating: 1**